James E. Levine Acquires 30,000 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) CFO James E. Levine purchased 30,000 shares of the business’s stock in a transaction on Friday, September 10th. The stock was acquired at an average cost of $6.47 per share, with a total value of $194,100.00. Following the completion of the acquisition, the chief financial officer now directly owns 5,000 shares in the company, valued at approximately $32,350. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of NASDAQ CRDF opened at $6.51 on Wednesday. The stock has a market cap of $257.48 million, a PE ratio of -9.43 and a beta of 1.78. The business has a fifty day moving average of $6.14 and a two-hundred day moving average of $7.89. Cardiff Oncology, Inc. has a 52-week low of $4.88 and a 52-week high of $25.50.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings data on Thursday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.07 million. Cardiff Oncology had a negative net margin of 5,830.38% and a negative return on equity of 21.65%. Equities analysts forecast that Cardiff Oncology, Inc. will post -0.68 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in shares of Cardiff Oncology by 86.7% during the first quarter. JPMorgan Chase & Co. now owns 3,735 shares of the company’s stock valued at $35,000 after acquiring an additional 1,734 shares during the period. Northern Trust Corp increased its stake in shares of Cardiff Oncology by 4.7% in the first quarter. Northern Trust Corp now owns 46,597 shares of the company’s stock valued at $431,000 after buying an additional 2,077 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Cardiff Oncology by 55.7% in the first quarter. Royal Bank of Canada now owns 14,200 shares of the company’s stock valued at $131,000 after buying an additional 5,081 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Cardiff Oncology in the second quarter valued at $36,000. Finally, Geode Capital Management LLC increased its stake in shares of Cardiff Oncology by 2.7% in the first quarter. Geode Capital Management LLC now owns 208,455 shares of the company’s stock valued at $1,930,000 after buying an additional 5,569 shares in the last quarter. 67.11% of the stock is owned by institutional investors.

A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Thursday, August 12th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Cardiff Oncology in a research report on Thursday, September 9th. Finally, Maxim Group raised their target price on Cardiff Oncology from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, September 9th.

About Cardiff Oncology

Cardiff Oncology, Inc is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.

Featured Story: Dual Listing What You Need to Know

Insider Buying and Selling by Quarter for Cardiff Oncology (NASDAQ:CRDF)

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.